PMID: 18196620Jan 16, 2008Paper

A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)

Current Medical Research and Opinion
Jun-ren ZhuCharn Sriratanasathavorn

Abstract

Most studies investigating the benefits of statins have focused on North American and European populations. This study focuses on evaluating the lipid-lowering effects of rosuvastatin and atorvastatin in Asian patients. The DIrect Statin COmparison of LDL-C Values: an Evaluation of Rosuvastatin therapY (DISCOVERY)-Asia study is one of nine independently powered studies assessing the efficacy of starting doses of statins in achieving target lipid levels in different countries worldwide. DISCOVERY-Asia was a 12-week, randomised, open-label, parallel-group study conducted in China, Hong Kong, Korea, Malaysia, Taiwan, and Thailand. A total of 1482 adults with primary hypercholesterolaemia and high cardiovascular risk (> 20%/10 years, type 2 diabetes, or a history of coronary heart disease) were randomised in a 2 : 1 ratio to receive rosuvastatin 10 mg once daily (o.d.) or atorvastatin 10 mg o.d. The percentage of patients achieving the 1998 European Joint Task Force low-density lipoprotein cholesterol (LDL-C) goal of < 3.0 mmol/L at 12 weeks was significantly higher in the rosuvastatin group (n = 950) compared with the atorvastatin group (n = 471) (79.5 vs. 69.4%, respectively; p < 0.0001). Similar results were observed for 1998 Eu...Continue Reading

References

Aug 11, 1998·International Journal of Epidemiology·P TatsanavivatT Yipintsoi
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Aug 18, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·M K ItoM A Aldridge
May 2, 2002·Journal of Cardiovascular Risk·Hapizah M NawawiKhalid Yusoff
Jul 16, 2003·The American Journal of Cardiology·Peter H JonesUNKNOWN STELLAR Study Group
Mar 24, 2004·Journal of Atherosclerosis and Thrombosis·Yasushi SaitoAli Raza
Apr 10, 2004·Cardiology·Donald G VidtHoward G Hutchinson
Apr 13, 2004·American Heart Journal·Herbert SchusterUNKNOWN Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group
Jun 10, 2004·The Annals of Pharmacotherapy·Michael G Kendrach, Maisha Kelly-Freeman
Jul 17, 2004·Journal of Atherosclerosis and Thrombosis·Hiroshi MabuchiMasahiro Nii
Oct 7, 2004·The American Journal of Cardiology·James ShepherdHoward G Hutchinson
Apr 6, 2005·The Journal of Pharmacy and Pharmacology·E H JangJ H Kang
May 25, 2005·Journal of Internal Medicine·B H R WolffenbuttelUNKNOWN Dutch Corall Study Group
Aug 9, 2005·Current Medical Research and Opinion·Francisco A H FonsecaUNKNOWN DISCOVERY PENTA investigators
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Rommel G Tirona
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Edmund LeeDennis Schneck
Dec 15, 2005·International Journal of Clinical Practice·A F E BotsUNKNOWN Discovery Netherlands Investigators
Jan 13, 2006·JAMA : the Journal of the American Medical Association·Deepak L BhattUNKNOWN REACH Registry Investigators
Jan 24, 2006·American Journal of Therapeutics·Augustine M ManadanJoel A Block
Apr 4, 2006·The American Journal of Cardiology·Malcolm Law, Alicja R Rudnicka
Apr 4, 2006·The American Journal of Cardiology·Mark J CzirakyMichael H Davidson
May 10, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·K G M M AlbertiJ Shaw
May 27, 2006·The American Journal of Cardiology·Donald G VidtJonathan M Sorof
Aug 19, 2006·BMJ : British Medical Journal·Yangfeng Wu
May 24, 2007·Current Hypertension Reports·Haralampos J MilionisDimitri P Mikhailidis

❮ Previous
Next ❯

Citations

May 21, 2010·Population Health Metrics·Junya PattaraarchachaiAlan D Lopez
Nov 3, 2011·Pharmacogenomics·Ping Wang
Jan 17, 2015·Chinese Medical Journal·Yi-Cong YeShu-Yang Zhang
Mar 28, 2008·Journal of the Chinese Medical Association : JCMA·Chern-En ChiangShih-Hsien Sung
Jun 2, 2015·Contemporary Clinical Trials·Emily PeckhamDavid J Torgerson
Aug 2, 2008·Expert Opinion on Pharmacotherapy·Handrean Soran, Paul Durrington
Aug 16, 2016·Cardiovascular Therapeutics·Juliana C N ChanRachel Laskey
Nov 22, 2014·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Jun 24, 2009·Circulation·Antonio M Gotto
Jul 22, 2008·Pharmacoepidemiology and Drug Safety
Feb 5, 2010·Clinical Pharmacology and Therapeutics·B TomlinsonE K Li
Apr 22, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Gillian M Keating, Dean M Robinson
Aug 30, 2017·International Journal of Endocrinology and Metabolism·Meor Fairuz Rizal Meor Anuar ShuhailiSubashini C Thambiah
Dec 25, 2008·Current Opinion in Lipidology
Sep 30, 2021·Cardiology and Therapy·Konstantinos TsioufisJoris van Vugt

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.